Skip to main content

Targeting newly discovered oxygen-sensing cascades for novel cancer treatments Biology, equipment, drug candidates.

Objective

The last decade's basic and clinical oncology research has revealed a number of so far unrecognised regulating responses (e.g. HIF-1) in cells exposed to hypoxia. These processes have been proven highly important for embryonic development and survival and seem to have a major impact on tumour progression and resistance to radiotherapy and certain types of chemotherapy. Because of their strong over-expression in solid cancer tumours in comparison to adjacent normal tissue of these processes, this new knowledge may open a therapeutic window for cancer treatment by utilising hypoxia-responsive processes as drug targets.

Major EU stakeholders in academic research and industry will therefore explore and validate these new molecular targets as a necessary step in the preclinical development of innovative new diagnostics and treatment.

Our committee has identified the outstanding basic problems to be solved over the first 2 to 3 years in order to allow a successful drug development. These include: dissection of relevant steps in cancer cell response to hypoxia, development of the technology platform needed, further identification and characterisation ofmarker/target molecules, and initial in vitro drug development. Our own mid-term evaluation will then select which hypoxic processes may be suitable as targets for cancer-specific treatment.

Simultaneously, we will study diagnostic tagging and therapeutic strategies leading up to a selection process of promising compounds to be further developed after the end of the project period. The new treatments will be developed along two lines: targeting known cytostatics towards the newly discovered hypoxia-responsive molecules and searching for so far unused compounds, preferably toxic to pathways active during hypoxia. The final effort will be to ensure continued (EU) industry utilisation of our results.

Call for proposal

FP6-2002-LIFESCIHEALTH
See other projects for this call

Funding Scheme

IP - Integrated Project

Coordinator

AALBORG UNIVERSITY
Address
Fredrik Bajers Vej 5
Aalborg
Denmark

Participants (25)

ALBERT LUDWIGS UNIVERSITY FREIBURG
Germany
Address
Fahnenbergplatz
Freiburg
ASTRAZENECA UK LIMITED
United Kingdom
Address
15 Stanhope Gate
London
AVENTIS PHARMA
France
Address
13 Quai Jules Guesde
Vitry Sur Seine
CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Address
University Offices, Wellington Square
Oxford
CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN, CAMPUS VIRCHOW KLINIKUM, BERLIN, GERMANY
Germany
Address
Augustenburger Platz 1
Berlin
DEUTSCHES HERZZENTRUM MÜNCHEN, KLINIK AN DER TU MÜNCHEN
Germany
Address
Lazarettstr. 36
München
FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG
Germany
Address
Schlossplatz 4
Erlangen
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
United Kingdom
Address
Exhibition Road, South Kensington
London
INSTITUTE OF BIOTECHNOLOGY
Lithuania
Address
Graiciuno 8
Vilnius
INSTITUTE OF VIROLOGY, SLOVAK ACADEMY OF SCIENCES
Slovakia
Address
Dubravska Cesta 9
Bratislava
JOBST TECHNOLOGIES GMBH
Germany
Address
Stefan Meier Str. 8
Freiburg
KAROLINSKA INSTITUTET
Sweden
Address
Nobels Väg 1
Stockholm
LEA MEDIZINTECHNIK GMBH
Germany
Address
Winchesterstrasse 2
Giessen
LEO PHARMA A/S
Denmark
Address
Industriparken 55
Ballerup
MAASTRO INNOVATIONS BV
Netherlands
Address
Dr. Tanslaan 12
Maastricht
OXFORD BIOMEDICA PLC
United Kingdom
Address
Robert Robinson Ave
Oxford
RINA-NETZWERK RNA TECHNOLOGIEN GMBH
Germany
Address
Takustr. 3
Berlin
THE UNIVERSITY OF OSLO
Norway
Address
Problemveien 7
Oslo
THE VICTORIA UNIVERSITY OF MANCHESTER
United Kingdom
Address
Oxford Road
Manchester
ULLEVÅL UNIVERSITY HOSPITAL
Norway
Address
Kirkeveien 166
Oslo
UNIVERSITEIT MAASTRICHT/RESEARCH INSTITUTE GROW
Netherlands
Address
P.debeyelaan 25
Maastricht
UNIVERSITY COLLEGE LONDON
United Kingdom
Address
Gower Street
London
UNIVERSITY OF FLORENCE, DEPARTMENT OF CHEMISTRY
Italy
Address
Piazza S. Marco 4
Firenze
UNIVERSITY OF ZURICH
Switzerland
Address
Raemistrasse 71
Zurich
VIVOX APS
Denmark
Address
Gustav Wieds Vej 10B
Aarhus C